Clinical Trials in Boston

Showing 11941-11960 of 17,836 trials

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

NCT02614560

This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a planned stem cell transplant, or as maintenance therapy after a stem cell transplant. The main purpose of the study is to find the best dose and determine the anti-leukemic activity of vadastuximab talirine, given either pre- or post-allogeneic stem cell transplant (alloSCT) for adults with relapsed or refractory AML. This will be determined by assessing the safety and tolerability of vadastuximab talirine. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.

Acute Myeloid Leukemia

Seagen Inc.14 participantsStarted Nov 2015

Duarte, California, United States • Denver, Colorado, United States • Tampa, Florida, United States +8 more locations

COMPLETEDPhase 3< 1 mile

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

NCT00678392

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.

Kidney Neoplasms

Pfizer723 participantsStarted Sep 2008

Burbank, California, United States • Burbank, California, United States • Downey, California, United States +291 more locations

A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Find Trials by Condition in Boston

Tivozanib for Recurrent Glioblastoma

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Post-Traumatic Stress Symptoms (PTSS) in Transplant Recipients

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Digital Tools for Coping With Chronic Pain

Protective Ventilation With Higher Versus Lower PEEP During General Anesthesia for Surgery in Obese Patients

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer